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Phosphorylation-dependent protein–protein interaction has rarely been targeted in medicinal chemistry. 
Thymoquinone, a naturally occurring antitumor agent, disrupts prephosphorylated substrate recognition 
by the polo-box domain of polo-like kinase 1, a key mitotic regulator responsible for various 
carcinogenesis when overexpressed. Here, crystallographic studies reveal that the phosphoserine/
phosphothreonine recognition site of the polo-box domain is the binding pocket for thymoquinone and its 
analogue poloxime. Both small molecules displace phosphopeptides bound with the polo-box domain in a 
slow but noncovalent binding mode. A conserved water bridge and a cation−π interaction were found as 
their competition strategy against the phosphate group. This mechanism sheds light on small-molecule 
intervention of phospho-recognition by the polo-box domain of polo-like kinase 1 and other phospho-
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ABSTRACT: Phosphorylation-dependent protein-protein interaction has rarely been targeted in medicinal chemistry. Thymoqui-
none, a naturally occurring antitumor agent, disrupts pre-phosphorylated substrate recognition by the polo-box domain of polo-like 
kinase 1, a key mitotic regulator responsible for various carcinogenesis when over-expressed. Here, crystallographic studies reveal 
that the phosphoserine/phosphothreonine recognition site of the polo-box domain is the binding pocket for thymoquinone and its 
analogue poloxime. Both small molecules displace phosphopeptides bound with the polo-box domain in a slow but non-covalent 
binding mode. A conserved water bridge and a cation-π interaction were found as their competition strategy against the phosphate 
group. This mechanism shed lights on small-molecule intervention of phospho-recognition by the polo-box domain of polo-like 
kinase 1 and other phospho-binding proteins in general.  
Thymoquinone (TQ) is the main therapeutic ingredient extracted from Nigella sativa with medical application for centuries.1 Its 
anti-proliferative effect covers a wide range of tumor cell lines and in vivo models.1-9 Its safety was underscored in the recent Phase 





3 phases, involving mitotic regulators such as p53 protein, nuclear factor-kappa B and caspase-8.7-
9 However, the molecular targets of TQ remained elusive until the polo-box domain (PBD) of polo-like kinase 1 (Plk1) was pro-
posed.11 
Plk1 is an essential promoter of M Phase progression and its unchecked expression at G2/M Phase
12 leads to carcinogenesis in 
many TQ-sensitive tumor types.2, 6, 7, 13 While a number of inhibitors were developed to disrupt the kinase domain of Plk1,14 its non-
catalytic PBD emerged as an alternative target. PBD guides the catalytic domain to pre-phosphorylated substrates by recognizing a 
Ser-pSer/pThr core motif15 and, as shown by Reindl et al.,11 TQ disrupts this process, delocalizes Plk1 and eventually arrests the 
cell cycle.  
Though a few non-peptidic inhibitors against Plk1-PBD have been identified,11, 16, 17 how TQ or any of them blocks the phospho-
substrate recognition remained unknown due to the undetermined inhibitor binding site and the mechanism.11, 18 Covalent modifica-
tion was proposed based on the on-set time dependency of TQ11 and the fact that the quinone ring has Michael acceptor carbons 
capable of reacting with thiol groups on surface cystein residues.  
Moreover, Reindl et al. found the multiple targeting of phospho-recognition proteins by TQ, including Chk2 FHA domain and 
Pin1 WW domain which recognize pSer/pThr motif, and Src homology 2 (SH2) domain of STAT3 which binds to pTyr epitope.11 
This may suggest a specific binding mode of TQ to phospho-recognition sites. Targeting phospho-signaling by blocking pTyr rec-
ognition remains challenging to date.19 Besides, there's no definitive mechanistic elucidation to the small-molecule inhibition of 
PBD, one of the rarely tapped pSer/pThr binding domains. Structural evidence of TQ inhibiting phospho-recognition by Plk1 PBD 
may explain the time-dependency and reveal a mechanism of small molecule intervention of phospho-recognition.  
In this work we present a TQ-complexed Plk1-PBD crystal structure (PBDT, 2.75 Å; crystallographic data in Supplementary Ta-
ble S1). We tried to soak poloxin, a known Plk1-PBD inhibitor,11 into PBD crystals but only found electron density for the oxime 
fragment of poloxin (PBDP, 1.93 Å; crystallographic data in Supplementary Table S1). We therefore named this TQ analogue po-
loxime (PXE), a combination of “poloxin” and “oxime”. As expected, PXE is a hydrolysis product of poloxin, confirmed with liq-
uid chromatography-mass spectrometry (Supplementary Figure S1a-b). The lower occupancy of PXE may explain its higher B-
factor than that of TQ (Supplementary Table S1). We further determined a native PBD crystal structure (PBDApo, 1.95 Å; crystallo-




    
 
 
Figure 1. (a–b) Ribbon diagram of PBDT chain A (Lemon) and PBDP chain A (Pink). Residues around TQ (Yellow) and PXE (Magenta) 
are presented. Glycerol molecules are shown in grey and water molecules as red balls.2mFo-DFc electron density maps (blue wire mesh) 
of TQ and PXE are contoured at 1 σ. (c) PBDT chain A  is superimposed onto Protein Data Bank entry 3BZI, both colored by secondary 
structure (α-helix: blue, β-sheet: coral and others: white). TQ (Yellow) and a glycerol molecule (Grey) are shown. The phosphopeptide in 
3BZI is shown in dark green (Non-carbon atoms are colored as N: blue, O: red and P: magenta). Hydrogen bonds between the phosphate 
and the Lys540-His538 pincer are shown in dotted lines. Red balls represent water molecules in 3BZI.
PBDT and PBDP pinpointed the inhibitor binding site: the phosphate group recognition site between the two polo boxes of the 
PBD, each consisting of an α helix and a β sheet (Figure 1a–b). This pocket consists of a hydrophobic half (Val411, Trp414, 
Leu490 and Leu491) and a positively charged half (His538, Lys540 and Arg557) where the Lys540-His538 pincer clinches phos-
phopeptides by the phosphate (Figure 1c).20 A glycerol molecule is found near the bound ligands, occupying the Ser-1 position for 
phosphopeptide binding, which is observed in other PBD crystal structures as well.15 
Pre-phosphorylation of Plk1 substrates (e.g. p-Cdc25c, Figure 1c) is critical for the PBD recognition15, 20 and accounts for supe-
rior binding affinity by several orders of magnitude compared to their non-phosphorylated versions, which was found almost non-
binding by Huggins et al. using isothermal titration calorimetry.21 However, a PBD crystal structure with a non-phosphorylated 
peptide is available14. This can be explained by the law of mass: the co-crystallography is done with high concentrations of both the 
protein and the peptide. Since the phosphate group functions as a turnkey in phosphorylation-dependent signaling pathways, the 
PBDT structure suggests that TQ jams the keyhole, preventing Plk1 from recognizing its mitotic substrates via PBD, and may sub-
sequently promote cell-cycle arrests and apoptosis. This corroborates with the G2/M Phase arrests in both TQ-centered
3 and Plk1-








Figure 2. (a-b) TQ (Yellow) and PXE (Magenta) in contact with a structural water (W1), respectively. TQ/PXE-bound structures (Lemon 
and Pink) are superimposed onto PBDP chain B (White) as a native structure. Atoms are colored by model except non-carbon atoms of the 
PBDT/PBDP side chains (N: blue, O: red). Glycerol molecules are CPK colored. Hydrogen bonds are given as red dashed lines. Arrows 
show the shift of Leu491. 
The binding of TQ and PXE has no apparent disruption of PBD compared to the native structure except for a ~2 Å positional 
shift in Leu491 side chain (Arrow, Figure 2a–b). In fact, the entire Leu491-Leu492 back bone was slightly pushed away to allow 
entry of two interfacial water molecules (W8 and W9) in PBDP or PBDT. Lys540 has close contact with both ligands while the im-
idazole ring of His538 is slightly turned but not close enough (>3.5 Å to the nearest carbon of TQ/PXE) to make interaction. What's 
more, we found the pocket extensively hydrated by crystallographic water molecules (W1–W11, Figure 2a-b), which makes no 
extra space for bulk solvent (Figure S3a). The binding of TQ/PXE is in effect a displacement of several crystallographic waters 
(W5–7). When bound, PXE is buried in a network of structural waters (Figure S3c), which should be the same case of TQ binding 
but water molecules can hardly be identified due to the lower resolution (Figure S3b).  
Reindl et al. did not observe a covalently bound inhibitor to PBD with mass spectrometry so as to explain time-dependent inhibi-
tion.11 Neither does TQ/PXE have covalent bonds with PBD as shown by the crystal structures nor do they mimic a charged phos-
phate. The question becomes what directed the binding of TQ/PXE to the phosphate binding site and why time-dependency. A fluo-
rescence polarization based assay11 was used to characterize TQ and PXE’s binding kinetics by tracing the unbound PBD with fluo-
rescently labeled phosphopeptide. The IC50 values of both TQ and PXE inhibiting the phosphopeptide binding were tracked (Sup-
plementary Figure S2). The dropping of IC50s slowed down remarkably after a quick slump and the Hill slope values were converg-
ing to 1(Supplementary Table S2a, 2c). These indicate competitive binding instead of inactivation due to covalent modification. We 
initiated dissociation of pre-incubated TQ/PXE-PBD with dithiothreitol, which neutralizes TQ and PXE containing Michael accep-
tors. However, due to the limited time frame we weren't able to see complete dissociation of PXE, while TQ did not display signifi-
cant dissociation (Supplementary Table S2b, 2d). The dissociation of PXE casts doubt on covalent modification and supports com-
petitive binding as a viable theorem. The glycerol molecule adjacent to TQ and PXE has contacts with both ligands but glycerol, up 
to 30% in the buffer, had no effect in neither the peptide binding or the TQ/PXE inhibition (Data not shown). 
A recent study of shielded hydrogen bonds as the determinant of binding kinetics may uncover the mechanism of the slow bind-
ing of TQ and PXE.22 In their work the almost buried polar atoms (ABPA) of the receptor are found responsible of slow ligand 
binding as the solvent accessible surface area of the ABPA (A0) is less than 10 Å
2 and the binding site is concave (∆A<0, A0 de-
creases as the probe size increases). Such slow-dissociating ligand-receptor pair is exemplified by biotin-streptavidine of which the 
dissociation rate constant can be 100 fold smaller23 than that of TQ-PBD, presumably because of those water-shielded hydrogen 
bonds.  
The structural feature of the PBD binding pocket is a similar case as a structural water (W1, Figure 2) serves as an ABPA (A0 = 
2.96Å2, ∆A<0) which, once with a hydrogen bond with TQ/PXE, is completely shielded from bulk solvent (A0 = 0). The V-shaped 






electric effect by bulk solvent and strengthening the hydrogen bonding between the W1 and TQ/PXE. Both the narrow pocket and 
TQ/PXE are steric impediment themselves, preventing bulk solvent from coming in to contact with W1 before ligand dissociation. 
Similarly, the kinetic barrier of TQ/PXE association should largely come from the dissociation of W5, which shields W1 from bulk 
solvent as well. In fact, as aforementioned, the narrow and deep pocket doesn't have space for bulk solvent at all (Supplementary 
Figure S3a), which means all three structural water molecules (W5–W7, Figure 2a-b) have to dissociate before TQ/PXE can access; 
accordingly, TQ/PXE has to move out of the pocket before water can refill it. Such empty-pocket transition state must be energeti-
cally unfavorable and kinetically penalized. Consistently, due to the smaller size of water than TQ/PXE, steric impediment is less 
significant for water, which explains the much slower dissociation of TQ/PXE than their respective association. 
 
 
Figure 3. (a) Root mean square fluctuation of crystallographic waters averaged over the first 4 ns simulation. Dashed line represent y=3.0. 
W1 is shown as a red square. (b) W1 (as ball and stick) and nearby residues (as cylinders), added with hydrogen and energetically mini-
mized. Atoms are CPK colored. Blue and red dashed lines represent hydrogen bonds between W1 and Asn533/Val411, respectively, of 
which the lengths are plotted as radial distribution function in (c), where the blue and red curves peak at the most probable radius within 
the 4 ns.  
In addition, we assessed the mobility of crystallographic waters with a 6 ns molecular dynamics simulation to verify the role of 
W1 as a structural water that needs to be treated as a part of the receptor. We tracked the trajectory and found W1 showing little 
movement during the first 4 ns, together with other 2 waters below 3 Å of root mean square fluctuation (RMSF) (Figure 3a). W1, 
the only conserved water in the phosphate binding pocket, oscillated between Asn533ND2 (a hydrogen donor) and Val411O (a 
hydrogen acceptor). Their bond lengths are demonstrated in the plot of radial distribution function (RDF): the red peak (2.75 Å) for 
the most-likely distance between W1O and Val411O, and the blue peak (3.15 Å) for that of W1O and Asn533ND2 (Figure 3b, 2c). 
Such arrangement enables W1 to bridge the binding of either a hydrogen acceptor (carbonyl O7of TQ) or a potential hydrogen do-
nor (PXE's oxime O13): W1 makes two hydrogen bonds in both cases, one with the receptor, the other with the ligand. Additional-
ly, W1 is buried deeply in the pocket and not available in phosphopeptide positioning. TQ/PXE are capable of penetrating the hy-
drogen bond network made by crystallographic waters by slowly displacing them and eventually anchor themselves on the con-
served W1, while a phosphate group can only recruit waters with much higher mobility.21 
Both TQ and PXE lack the negative charges of a phosphate group which allows it to be attracted by the protonated Lys540. They 
nevertheless overlap with the phosphate when the protein structures are superimposed and are particularly close to Lys540. We 
suspected there is a cation- interaction between the protonated lysine Nζ and TQ/PXE's cross-conjugated systems, which may 









Figure 4. The shortest inter-molecular distances between Lys540+ and TQ(a)/PXE(b) are represented as dashed lines. Atoms are CPK 
colored. 
Table 1. MP2 calculated interaction energies (kcal/mol) 
 EHFa EMP2a Ecorr
b 
Lys540-TQ    
6-31G(0.25) -0.89 -6.52 -5.63 
6-311+G() -0.30 -5.77 -5.47 
Lys540-PXE    
6-31G(0.25) -0.09 -8.37 -8.28 
6-311+G() 0.72 -7.62 -8.34 
a Gas-phase intermolecular interaction energies (in kcal/mol) at the MP2 level (EMP2) and HF level (EHF) after BSSE correc-
tion. b The dispersion energy was defined as Ecorr = EMP2 - EHF. 
Since the current molecular mechanics force fields do not explicitly account for cation- interaction and likely the cause of both 
TQ and PXE being drawn to Arg557 during MD simulations of PBDT and PBDP respectively (data not shown), we turn to quantum 
mechanical calculations to see if TQ or PXE nevertheless make use of the Lys540 albeit lacking net negative charges. Lys540Nζ+ 
is located on top of C6 in the TQ/PXE-bound structures, and thus Nζ+-C6 is nearly vertical to the -C2=C1-C6=O7/N7- plane (Figure 
4a-b). Considering that C6 is a local geometric centre of the cross-conjugated systems consisting two alkenes (C4=C5 and C1=C2), 
and a carbonyl/oxime group, Nζ+ is on a favourable spot for making cation-π interaction.We did ab initio quantum mechanical 
calculations of interaction energy, defined as the energetic difference between the complex (Ecomplex) and the monomers (Eligand and 
Eprotein), at Hartree-Fock (HF) and the MP2 levels using 6-31G (0.25) and 6-311+G() basis set. The basis set superposition error 
(BSSE) was corrected using the Boys and Bernardi counterpoise method.24 The calculated interaction energies (Table 1) are of sig-
nificant magnitude, suggesting that the protonated Lys540 remarkably stabilizes TQ/PXE-PBD complexes. Comparison of MP2 
and HF interaction energies shows a substantial correlation correction, which indicates that in addition to electrostatic interactions, 
dispersion energies (electron correlation effect) contribute substantially to the cation-π interaction. The reduced dielectric effect due 
to the lack of nearby bulk solvent should be favourable of such interaction. This solvent shielded interaction should have a similar 
effect to the binding kinetics just as the solvent shielded hydrogen bond.  
A number of phospho-recognition protein has emerged with a variety of functions with regard to phosphorylation-dependent sig-
naling and cell cycle control, including 14-3-3,25 BRCA1 carboxyl terminal domains,26 FHA domains27 and the aforementioned 






pho-recognition pockets as Plk1 PBD does,20 such cation-π interaction may be a general phenomenon and explains the non-
specificity of TQ.  
Although having potentially reactive α, β-unsaturated carbons, TQ is the only small-molecule inhibitor of pSer/pThr/pTyr recog-
nition with actual therapeutic application in intervening cell cycle signalling to our knowledge. Unlike phosphonate, sulphonate or 
carboxylic compounds as phosphate mimics which have poor membrane permeability, TQ is moderately hydrophobic and bears 
zero net charge, yet utilizing the targets' structural features for phosphate-binding just the same. In fact, other PBD inhibitors may 
use the same strategy since they have substructures that resemble TQ. A pan-specific PBD inhibitor16 has a cross-conjugated hex-
atomic ring system with a carbonyl terminus and a large group similar to the isopropyl group of TQ. Purpurogallin17, another PBD 
inhibitor with a cross-conjugated system in a heptatomic ring, similarly has a carbonyl terminus and a combined ring at the position 
of the isopropyl group of TQ. They could adopt the same orientation of TQ/PXE when binding to PBD and have interactions with 
the structural water and the Lys540. As the candidate pool of PBD inhibitors expands, we will learn more about the structural basis 
of phospho-recognition inhibition of PBD. The complex structures herein offer a new perspective of the energetic nature of 
TQ/PXE's competition of phosphopeptide binding to Plk1 PBD. The phospho-mimicry mechanism may benefit medicinal design 
targeting PBD and other phospho-binding domains in general. 
METHODES 
Plk1-PBD constructs, residue range 326-603 for assay and residue range 367-603 for crystallography, were cloned, expressed and purified. 
Crystallization was carried out by vapor diffusion at 18 ºC in 1.4 M sodium potassium tartrate, 50 mM MES, pH 6.5, and 100 mM Hepes, 
pH 6.0. TQ/PXE were soaked into the crystals. Diffraction data sets were collected at wavelength 0.98 Å, 100 k, at the Beamline 17U, 
Shanghai Synchrotron Radiation Facility (SSRF). Structure was solved by molecular replacement using Protein Data Bank entry 1UMW as 
search models. Data collection and refinement statistics are reported in Table S1. Full details are given in the Supporting Information on-
line. 
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